COVID-19 - Cipla's remdesivir Cipremi launched in India, to cost ₹4,000
Cipla has launched the generic version of COVID-19 treatment drug remdesivir at a price which is among the lowest globally, according to a PTI report. The pharma major is looking to supply over 80,000 vials within the first month. The drug is priced at ₹4,000 per 100 mg vial, Cipla said in a statement.
Remdesivir is the only drug approved by United States Food and Drug Administration (USFDA) for Emergency Use Authorisation (EUA) treatment of adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection.
Cipla had earlier said the drug will be priced at less than ₹5,000 per 100 mg vial in line with its overall philosophy of driving access and affordability.
Covaxin, India's first possible vaccine against COVID-19 will soon start its human trial. The proess had already been initiated by Nizam's Institute of Medical Sciences (NIMS). Developed by Bharat Biotech, the Covaxin will be tested on over 1,100 people in two phases. The company had a plan to enroll 375 participants to test COVID-19 vaccine candidate this month